Pharma Group Pans FDA Guidance On Off-Label Info Sharing
A drug industry group blasted the U.S. Food and Drug Administration's draft guidance on how companies can respond to unsolicited questions about off-label uses, contending in public comments last week that...To view the full article, register now.
Already a subscriber? Click here to view full article